Literature DB >> 29218263

Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities.

Bhadrasain Vikram1.   

Abstract

Entities:  

Year:  2017        PMID： 29218263      PMCID： PMC5709128          DOI： 10.21037/tlcr.2017.09.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  8 in total

1.  SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Authors:  Jan Nyman; Andreas Hallqvist; Jo-Åsmund Lund; Odd-Terje Brustugun; Bengt Bergman; Per Bergström; Signe Friesland; Rolf Lewensohn; Erik Holmberg; Ingmar Lax
Journal:  Radiother Oncol       Date:  2016-09-03       Impact factor: 6.280

2.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

3.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

4.  A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Authors:  Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-17       Impact factor: 7.038

Review 5.  Effects of Charged Particles on Human Tumor Cells.

Authors:  Kathryn D Held; Hidemasa Kawamura; Takuya Kaminuma; Athena Evalour S Paz; Yukari Yoshida; Qi Liu; Henning Willers; Akihisa Takahashi
Journal:  Front Oncol       Date:  2016-02-12       Impact factor: 6.244

6.  Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Authors:  Corinne Faivre-Finn; Michael Snee; Linda Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; Susan Harden; Cecile Le Pechoux; Rhona McMenemin; Nazia Mohammed; Mary O'Brien; Jason Pantarotto; Veerle Surmont; Jan P Van Meerbeeck; Penella J Woll; Paul Lorigan; Fiona Blackhall
Journal:  Lancet Oncol       Date:  2017-06-20       Impact factor: 41.316

7.  Multiplatform-based molecular subtypes of non-small-cell lung cancer.

Authors:  F Chen; Y Zhang; E Parra; J Rodriguez; C Behrens; R Akbani; Y Lu; J M Kurie; D L Gibbons; G B Mills; I I Wistuba; C J Creighton
Journal:  Oncogene       Date:  2016-10-24       Impact factor: 9.867

Review 8.  Targeted Radionuclide Therapy: Practical Applications and Future Prospects.

Authors:  Katherine Zukotynski; Hossein Jadvar; Jacek Capala; Frederic Fahey
Journal:  Biomark Cancer       Date:  2016-05-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.